Anavex Life Sciences
|This article is an orphan, as no other articles link to it. Please introduce links to this page from ; try the Find link tool for suggestions. (February 2009)|
|Public OTCQB: AVXL|
|Headquarters||New York, New York, USA|
|Christopher U. Missling, MS, PhD, MBA, President and CEO
Tom Skarpelos, Director
Michael Gold, MD, Scientific Advisory Board
Ottavio Arancio, MD, PhD, Scientific Advisory Board
Tangui Nicolas Maurice, Ph.D., Scientific Advisory Board
Paul Aisen, MD, Scientific Advisory Board – Clinical Expert
Jeffrey Cummings, MD, Scientific Advisory Board – Clinical Expert
Anavex Life Sciences Corp. is a pharmaceutical company that develops drug candidates.
ANAVEX 2-73 has been shown to provide protection from oxidative stress, which damages and destroys neurons and is believed to be a primary cause of Alzheimer's disease. Research in recent years indicates that oxidative stress is a precursor to amyloid-beta plaques and tau (see also Neuro-Fibrillary Tangles), and could be a novel and appropriate therapeutic target.